In this role, Mr Mengler will be responsible for expanding the company’s generic business by growing capability in the US market while driving global opportunities.
Mr Mengler comes to Impax from Barr Laboratories, where he was most recently executive vice president of global strategic planning, responsible for the global cross-functional development of the generic product portfolio.
Mr Mengler has earned a BS in mathematical sciences and operations research from Johns Hopkins University, a BS in pharmacy from St John’s University, and his MBA from Bernard M Baruch College in New York.
Larry Hsu, president and CEO of Impax, said: “We are pleased that Mr Mengler will be joining Impax and leading our generics division. He is an accomplished executive with significant experience in key management positions including strategic planning and the development of Barr Laboratories generic R&D and commercial products portfolio. His addition further enhances our management team and will help improve our business results.”